Literature DB >> 1372154

Dual role of tumor necrosis factor-alpha in angiogenesis.

L F Fajardo1, H H Kwan, J Kowalski, S D Prionas, A C Allison.   

Abstract

The role of tumor necrosis factor-alpha (TNF; cachectin) in angiogenesis has been controversial. In vitro TNF inhibits proliferation of endothelial cells (EC) whereas in the cornea it appears to stimulate vessel growth. The authors tested TNF in their recently developed disc angiogenesis system (DAS), designed to measure the proliferation of microvessels. The DAS, implanted subcutaneously in mice, was either fitted with a central pellet containing mouse recombinant TNF (mrTNF), or exposed to mrTNF delivered subcutaneously by an osmotic minipump. Low doses of mrTNF (0.01-1 ng) induced angiogenesis, which was maximum at 0.1 ng, whereas high doses (1, and 5 micrograms) inhibited it. Subcutaneous mrTNF delivered at the (high) rate of 15-60 ng/hr for 14 days inhibited angiogenesis. These results indicate bimodal, dose-dependent opposing effects and explain some of the in vitro versus in vivo paradoxical results. TNF (native or exogenous) may have opposing effects on microvessels of neoplasms and inflammatory reactions, depending on its local tissue concentrations.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1372154      PMCID: PMC1886157     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  26 in total

Review 1.  The tumor necrosis factors: cachectin and lymphotoxin.

Authors:  B Beutler
Journal:  Hosp Pract (Off Ed)       Date:  1990-02-15

2.  Tumor necrosis factor in human disease.

Authors:  L F Fajardo; G E Grau
Journal:  West J Med       Date:  1991-01

3.  Effects of X irradiation on angiogenesis.

Authors:  S D Prionas; J Kowalski; L F Fajardo; I Kaplan; H H Kwan; A C Allison
Journal:  Radiat Res       Date:  1990-10       Impact factor: 2.841

Review 4.  Biologic activities and mechanisms of action of tumor necrosis factor-alpha/cachectin.

Authors:  M Jäättelä
Journal:  Lab Invest       Date:  1991-06       Impact factor: 5.662

Review 5.  Critical factors controlling angiogenesis: cell products, cell matrix, and growth factors.

Authors:  L T Furcht
Journal:  Lab Invest       Date:  1986-11       Impact factor: 5.662

6.  Mechanism of antitumor activity of tumor necrosis factor alpha with hyperthermia in a tumor necrosis factor alpha-resistant tumor.

Authors:  J M Srinivasan; L F Fajardo; G M Hahn
Journal:  J Natl Cancer Inst       Date:  1990-12-19       Impact factor: 13.506

7.  Immunohistochemical detection of bFGF and TNF-alpha in the course of inflammatory angiogenesis in the mouse cornea.

Authors:  C Sunderkötter; J Roth; C Sorg
Journal:  Am J Pathol       Date:  1990-09       Impact factor: 4.307

8.  In vivo angiogenic activity of interleukins.

Authors:  D BenEzra; I Hemo; G Maftzir
Journal:  Arch Ophthalmol       Date:  1990-04

9.  Tumor necrosis factor inhibits the proliferation of cultured capillary endothelial cells.

Authors:  L Schweigerer; B Malerstein; D Gospodarowicz
Journal:  Biochem Biophys Res Commun       Date:  1987-03-30       Impact factor: 3.575

10.  Capillary endothelial cell cultures: phenotypic modulation by matrix components.

Authors:  J A Madri; S K Williams
Journal:  J Cell Biol       Date:  1983-07       Impact factor: 10.539

View more
  88 in total

Review 1.  Current methods for assaying angiogenesis in vitro and in vivo.

Authors:  Carolyn A Staton; Stephen M Stribbling; Simon Tazzyman; Russell Hughes; Nicola J Brown; Claire E Lewis
Journal:  Int J Exp Pathol       Date:  2004-10       Impact factor: 1.925

2.  Vascular endothelial growth factor C promotes survival of retinal vascular endothelial cells via vascular endothelial growth factor receptor-2.

Authors:  Bojun Zhao; Gill Smith; Jun Cai; Aihua Ma; Mike Boulton
Journal:  Br J Ophthalmol       Date:  2006-08-30       Impact factor: 4.638

3.  Photodynamic therapy combined with a cysteine proteinase inhibitor synergistically decrease VEGF production and promote tumour necrosis in a rat mammary carcinoma.

Authors:  B Zsebik; K Symonowicz; Y Saleh; P Ziolkowski; A Bronowicz; G Vereb
Journal:  Cell Prolif       Date:  2007-02       Impact factor: 6.831

4.  Implementation and validation of an ultrasonic tissue characterization technique for quantitative assessment of normal-tissue toxicity in radiation therapy.

Authors:  Jun Zhou; Pengpeng Zhang; K Sunshine Osterman; Shermian A Woodhouse; Peter B Schiff; Emi J Yoshida; Zheng Feng Lu; Eliza R Pile-Spellman; Gerald J Kutcher; Tian Liu
Journal:  Med Phys       Date:  2009-05       Impact factor: 4.071

Review 5.  Angiogenesis drives psoriasis pathogenesis.

Authors:  Regina Heidenreich; Martin Röcken; Kamran Ghoreschi
Journal:  Int J Exp Pathol       Date:  2009-06       Impact factor: 1.925

6.  Obesity induced rapid melanoma progression is reversed by orlistat treatment and dietary intervention: role of adipokines.

Authors:  Parmanand Malvi; Balkrishna Chaube; Vimal Pandey; Maleppillil Vavachan Vijayakumar; Purushotham Reddy Boreddy; Naoshad Mohammad; Shivendra Vikram Singh; Manoj Kumar Bhat
Journal:  Mol Oncol       Date:  2014-11-26       Impact factor: 6.603

7.  Dual roles of tumor necrosis factor-alpha receptor-1 in a mouse model of hindlimb ischemia.

Authors:  Jun Jiang; Jianan Wang; Changling Li; Shan Ping Yu; Ling Wei
Journal:  Vasc Med       Date:  2009-02       Impact factor: 3.239

8.  Squamous carcinoma cells influence monocyte phenotype and suppress lipopolysaccharide-induced TNF-alpha in monocytes.

Authors:  Aroonwan Lam-ubol; Dustin Hopkin; Elena M Letuchy; Zoya B Kurago
Journal:  Inflammation       Date:  2010-08       Impact factor: 4.092

9.  E-selectin is present in proliferating endothelial cells in human hemangiomas.

Authors:  B M Kräling; M J Razon; L M Boon; D Zurakowski; C Seachord; R P Darveau; J B Mulliken; C L Corless; J Bischoff
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

10.  Differential effects of angiostatic steroids and dexamethasone on angiogenesis and cytokine levels in rat sponge implants.

Authors:  Y Hori; D E Hu; K Yasui; R L Smither; G A Gresham; T P Fan
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.